StockMarketWire.com - Phytopharm said no statistically significant effects or trends towards improvement were seen in the results from Phase II tests of early-stage Parkinson's suffers with its Cogane drug.

More than 400 people with the disease were randomly allocated to receive either Cogane 60 mg, 120 mg or 180 mg, or placebo, which was taken orally, once daily for up to 28 weeks.

Measurements were taken during the study to determine the efficacy, safety and tolerability of each dose of Cogane compared with placebo and also the systemic exposure to Cogane, it said.

"We are naturally disappointed with the outcome of this study of Coganeâ„¢ in patients with Parkinson's disease," said chief executive Tim Sharpington.

"Cogane had demonstrated encouraging efficacy in a wide range of industry standard pre-clinical models but this promise has not translated into clinically meaningful efficacy in this study," he said.


At 9:25am: [LON:PYM] Phytopharm share price was -8.12p at 1.88p



Story provided by StockMarketWire.com